

Carbetocin

Solution for Injection

MADE IN GERMANY



Carbetocin EVER Pharma is approved for room-temperature storage, providing greater convenience and flexibility in handling and transport.

Indicated for the prevention of postpartum haemorrhage due to uterine atony following delivery of the infant, whether by caesarean section or vaginal birth.

- **Room-temperature stable** – no refrigerated storage or cold-chain transport required, reducing logistical complexity and lowering storage and transport costs.
- **Available in both vials and ampoules** – to support diverse clinical preferences and practice environments.



www.everpharma.com



Carbetocin

Solution for Injection

MADE IN GERMANY

Indications	Indicated for the prevention of postpartum hemorrhage due to uterine atony.
Active Ingredient	Carbetocin
Excipients	Sodium dihydrogen phosphate dihydrate, Sodium acetate trihydrate, Mannitol, Sodium hydroxide (for pH adjustment), Hydrochloric acid (for pH adjustment), Water for injections
Presentations	■ 100 µg/1 ml solution for injection
Strengths	Each 1 ml of solution contains 100 microgramms of carbetocin.
Stability	■ Unopened: 24 months. Do not store above 30°C. ■ After 1st Opening: Use immediately
Primary Packaging	■ Type I colourless glass 1 ml ampoule (with a white identification ring and a blue dot indicating the pre-cut area). ■ Type I colourless glass 2R vial with a halobutyl rubber stopper, sealed with an aluminium crimp cap, covered with a plastic flip-off cap.
Pack sizes	1 or 5 ampoules per pack. 1 or 5 vials per pack.

Carbetocin EVER Pharma 100 micrograms/ml solution for injection. Composition: 1 ml of solution contains 100 micrograms of carbetocin. List of excipients: Sodium dihydrogenphosphate dihydrate, Sodium acetate trihydrate, Mannitol, Sodium hydroxide (for pH adjustment), Hydrochloric acid (for pH adjustment), Water for injections. Therapeutic indications: For the prevention of postpartum haemorrhage due to uterine atony. Contraindications: During pregnancy and labour before delivery of the infant. Carbetocin must not be used for the induction of labour. Hypersensitivity to carbetocin, oxytocin or to any of the excipients listed in section 6.1. Hepatic or renal disease. Serious cardiovascular disorders. Epilepsy. Side effects: Intravenous administration: Very common: Headache, Tremor, Hypotension, Flushing, Nausea, Abdominal pain, Pruritus, Feeling of warmth. Common: Anaemia, Dizziness, Chest pain, Dyspnoea, Metallic taste, Vomiting, Back pain, Chills, Pain. Not known: Hypersensitivity (including anaphylactic reaction), Tachycardia, Bradycardia which can lead to cardiac arrest, Arrhythmia, Myocardial ischaemia, and QT prolongation. In the clinical trials sweating was reported as sporadic cases. Intramuscular administration: Uncommon: Anaemia, Headache, Dizziness, Tachycardia, Hypotension, Chest pain, Nausea, Abdominal pain, Vomiting, Back pain, Muscular weakness, Chills, Pyrexia, Pain. Rare: Tremor, Flushing, Dyspnoea, Pruritus, Urinary retention. Not known: Hypersensitivity (including anaphylactic reaction), Bradycardia which can lead to cardiac arrest, Arrhythmia, Myocardial ischaemia, and QT prolongation. More information available in the summary of product characteristics. Only available on prescription. Last update: April 2025. Marketing Authorisation Holder: EVER Valinject GmbH, Oberburgau 3, 4866 Unterach am Attersee, Austria.